Iovance Biotherapeutics Inc. (2LB)
XSTU
Real-time Data
06:00 AM
Day's Range
7.2452 wk Range
1.55Overview - 2LB - Iovance Biotherapeutics Inc.
Key Statistics
Valuation
Enterprise Value
-113.63M
P/E (Trailing)
‪-6.33‬
EV / EBITDA
‪0.32‬
Profitability
Gross Margin
‪56.10%‬
Profit Margin
‪34.27%‬
Operating Margin
‪-151.12%‬
Return on Assets
‪-42.81%‬
Return on Equity
‪-55.96%‬
Ownership
Shares Outstanding
452.97M
Price stats
50-Day Avg
‪2.11‬
200-Day Avg
‪1.97‬
Peers - 2LB - Iovance Biotherapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XSTU.
- 2LBXSTUIovance Biotherapeutics Inc.+71.95%52-week change-6.33P/E (Trailing)‪34.27%‬Profit Margin
- 37TXSTUForte Biosciences, Inc.+86.11%52-week change-13.91P/E (Trailing)—Profit Margin
- 0QFXSTUModerna Inc.+83.17%52-week change-18.38P/E (Trailing)‪54.83%‬Profit Margin
- 3920XSTUSpyre Therapeutics, Inc.+81.45%52-week change-38.38P/E (Trailing)—Profit Margin
- 0MEXSTUTwist Bioscience Corporation+80.18%52-week change-84.15P/E (Trailing)‪50.72%‬Profit Margin
- 5NRXSTUNanobiotix S.A.+78.42%52-week change—P/E (Trailing)—Profit Margin
- 3O8XSTUOmeros Corp.+77.40%52-week change-323.00P/E (Trailing)—Profit Margin
Profile Summary - 2LB - Iovance Biotherapeutics Inc.
About
Iovance Biotherapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor infiltrating lymphocyte, or TIL, cell therapies for cancer. Its current portfolio centers on Amtagvi, an individualized cell therapy used in advanced melanoma, and Proleukin, which supports the…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
